ABSTRACT
Platelet glycoprotein IIb/IIIa (GPIIb/IIIa) receptor inhibitors are widely used to prevent thrombotic vascular events, especially in patients with acute coronary syndromes (ACS) or in those undergoing intravascular interventional procedures. The purpose of this chapter is to evaluate the quality and magnitude of the clinical trial evidence in support of their use. In addition, key issues regarding their optimal application in clinical practice will be discussed.
